90 related articles for article (PubMed ID: 16287616)
1. Pharmacodynamics of two different dosing regimens of tirofiban in citrate or PPACK anticoagulated blood.
Voss R; Grebe M; Pralle H; Tillmanns H; Matzdorff A
Platelets; 2005 Dec; 16(8):492-7. PubMed ID: 16287616
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
Kereiakes DJ; Lorenz T; Young JJ; Kukielka G; Mueller MN; Nanniazzi-Alaimo L; Phillips DR
J Thromb Thrombolysis; 2001 Oct; 12(2):123-7. PubMed ID: 11729363
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
Lakkis N; Lakiss N; Bobek J; Farmer J
Catheter Cardiovasc Interv; 2002 Aug; 56(4):474-7. PubMed ID: 12124955
[TBL] [Abstract][Full Text] [Related]
4. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
[TBL] [Abstract][Full Text] [Related]
6. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
Simon DI; Liu CB; Ganz P; Kirshenbaum JM; Piana RN; Rogers C; Selwyn AP; Popma JJ
Catheter Cardiovasc Interv; 2001 Apr; 52(4):425-32. PubMed ID: 11285593
[TBL] [Abstract][Full Text] [Related]
8. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment.
Lakings DB; Janzen MC; Schneider DJ
Coron Artery Dis; 2012 May; 23(3):208-14. PubMed ID: 22441136
[TBL] [Abstract][Full Text] [Related]
11. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
Walters DL; Ray MJ; Wood P; Perrin EJ; Bett JH; Aroney CN
Eur J Clin Invest; 2010 Feb; 40(2):139-47. PubMed ID: 20039931
[TBL] [Abstract][Full Text] [Related]
12. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention.
Danzi GB; Capuano C; Sesana M; Baglini R
Curr Med Res Opin; 2003; 19(1):28-33. PubMed ID: 12661777
[TBL] [Abstract][Full Text] [Related]
13. Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin.
Zhang HZ; Yu LH; Kim MH
Platelets; 2013; 24(5):339-47. PubMed ID: 22774770
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
[TBL] [Abstract][Full Text] [Related]
15. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.
White MM; Krishnan R; Kueter TJ; Jacoski MV; Jennings LK
J Thromb Thrombolysis; 2004 Dec; 18(3):163-9. PubMed ID: 15815877
[TBL] [Abstract][Full Text] [Related]
16. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.
Schneider DJ; Herrmann HC; Lakkis N; Aguirre F; Wan Y; Aggarwal A; Kabbani SS; DiBattiste PM
Am J Cardiol; 2002 Dec; 90(12):1421-3. PubMed ID: 12480064
[No Abstract] [Full Text] [Related]
17. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
[TBL] [Abstract][Full Text] [Related]
18. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
19. Reproducibility and temporal stability of ADP-induced platelet aggregation: comparison of the anticoagulants sodium citrate and D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone.
Horne WC; Anderson GM; Cohen DJ
Am J Hematol; 1991 Sep; 38(1):48-53. PubMed ID: 1897514
[TBL] [Abstract][Full Text] [Related]
20. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
